REGENXBIO 将来の成長
Future 基準チェック /26
REGENXBIOは、51.9%と33.9%でそれぞれ年率51.9%で利益と収益が成長すると予測される一方、EPSはgrowで56.2%年率。
主要情報
51.9%
収益成長率
56.16%
EPS成長率
| Biotechs 収益成長 | 25.5% |
| 収益成長率 | 33.9% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 14 May 2026 |
今後の成長に関する最新情報
Recent updates
Seeking Alpha • May 16
Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results
Summary REGENXBIO is downgraded from "Buy" to "Hold" due to regulatory setbacks and uncertain approval pathways. The company received a Complete Response Letter for RGX-121 (MPS II), faces an uncertain appeals process, and regulatory demands for more rigorous data. Positive phase 3 data for RGX-202 for DMD patients showed strong biomarker and functional results, but FDA Accelerated Approval on Surrogate endpoint remains uncertain for now. Upcoming catalysts include pivotal wet-AMD trial data in Q4 2026, but the cash runway only extends into early 2027, raising financing concerns. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 26
RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment
REGENXBIO's consensus analyst price target has been revised lower, with cuts ranging from about $1 to $12 as analysts factor in updated clinical timelines, recent FDA commentary around RGX-121 and the approach to rare disease, as well as upcoming pivotal readouts for key gene therapy programs. Analyst Commentary Recent research updates show that while several firms still carry positive ratings on REGENXBIO, they have been trimming price targets and highlighting a more cautious setup around regulatory risk, clinical execution, and timelines for key programs.ナラティブの更新 • Apr 11
RGNX: Future Pivotal Gene Therapy Readouts Will Drive Bullish Reassessment
Analysts have nudged their average price target for REGENXBIO slightly lower to reflect recent target cuts across firms, while still highlighting upcoming regulatory updates and pivotal readouts in Duchenne muscular dystrophy and wet age related macular degeneration as key drivers for their updated views. Analyst Commentary Recent research updates show that while upcoming data and regulatory milestones remain central to the REGENXBIO story, several price targets have been adjusted lower following the latest quarterly results and clinical updates.ナラティブの更新 • Mar 28
RGNX: Future Gene Therapy Milestones Will Drive Reassessment Despite Regulatory Uncertainty
Analysts have nudged their blended price target for REGENXBIO modestly lower by a few dollars to reflect recent reductions in firm level targets, while still pointing to upcoming regulatory updates and pivotal readouts across programs like RGX-202 and ABBV-RGX-314 as key factors in their outlook. Analyst Commentary Street research around REGENXBIO has tilted more cautious in recent weeks, with several price targets adjusted lower following the latest quarterly update, recent regulatory news and evolving views on the company’s gene therapy portfolio.ナラティブの更新 • Mar 12
RGNX: Future Gene Therapy Readouts Will Drive Reassessment Despite Regulatory Setbacks
Analysts have trimmed their average price targets on REGENXBIO, with cuts such as $32 to $30, $45 to $42 and $18 to $17. These changes reflect updated assumptions for slightly lower revenue growth and profit margins, partly offset by a modestly lower discount rate and a higher future P/E multiple.ナラティブの更新 • Feb 26
RGNX: Regulatory Resolution And Gene Therapy Data Will Drive Reassessment
Analysts have trimmed their price targets on REGENXBIO by up to $12, reflecting updated views on RGX-121 related regulatory uncertainty and revised assumptions for the discount rate, revenue growth, profit margin and future P/E, while the central fair value estimate remains at $12.00. Analyst Commentary Recent research updates around REGENXBIO have centered on RGX-121 and the regulatory commentary that investors are trying to interpret.ナラティブの更新 • Feb 11
RGNX: Clinical Hold Setbacks Will Refocus Attention On Upcoming Pivotal Data
Analysts have trimmed their fair value estimate for REGENXBIO to $12.00 from $14.00, citing a reset in price targets across the Street following clinical updates. The revised estimate still reflects higher modeled revenue growth and a lower future P/E multiple in their assumptions.分析記事 • Feb 06
REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Jan 29
Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 23
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 27% gain in the last month alone. The...分析記事 • Oct 09
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29%
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 29% gain in the last month alone...分析記事 • Oct 03
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 12
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel
NasdaqGS:RGNX 1 Year Share Price vs Fair Value Explore REGENXBIO's Fair Values from the Community and select yours With...
ナラティブの更新 • Aug 08
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.分析記事 • May 15
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for REGENXBIO Inc. ( NASDAQ:RGNX ), which a week ago released some disappointing...分析記事 • May 01
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Apr 24
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
新しいナラティブ • Mar 30
FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.Seeking Alpha • Mar 26
5 Reasons To Buy Regenxbio Right Now
Summary Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis. Technically speaking, the stock is shifting from bearish to bullish, with significant upside potential and positive price target trends from multiple analysts. RGNX is a prime buyout candidate, with AbbVie as a likely bidder, supported by several other potential suitors in the biotech and pharma sectors that are active/interested in Gene Therapy. Read the full article on Seeking Alpha分析記事 • Mar 04
The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%
To the annoyance of some shareholders, REGENXBIO Inc. ( NASDAQ:RGNX ) shares are down a considerable 27% in the last...Seeking Alpha • Jan 15
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Summary Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku. Despite historical underperformance, I remain hopeful, banking on the durability of their wet AMD treatment and will continue buying at dips, giving RGNX stock two more years. Read the full article on Seeking Alpha分析記事 • Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive
Unfortunately for some shareholders, the REGENXBIO Inc. ( NASDAQ:RGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 31
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Summary Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030. RGX-202 for the treatment of patients with DMD and ABBV-RGX-314 for treatment of patients with diabetic retinopathy are other programs in pipeline; Late-stage studies starting Q4 of 2024 and 1st half 2025 respectively. Read the full article on Seeking Alpha分析記事 • Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Aug 06
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Summary Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024. Subretinal delivery of ABBV-RGX-314 for the treatment of patients with Wet-AMD is ongoing; Two studies being done are ATMOSPHERE and ASCENT and regulatory submissions U.S. And EU on track for 1st half of 2026. Read the full article on Seeking Alpha分析記事 • Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that REGENXBIO Inc. ( NASDAQ:RGNX ) filed its quarterly result this time last week. The...分析記事 • Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
REGENXBIO Inc.'s ( NASDAQ:RGNX ) price-to-sales (or "P/S") ratio of 8.2x might make it look like a buy right now...Seeking Alpha • Jun 11
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Summary REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome. ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data. The collaboration with AbbVie for ABBV-RGX-314 includes potential milestone payments and significant market potential in wet AMD and DR. I deem RGNX a "strong buy" due to its innovative pipeline, strategic partnerships, robust financial health, and potential market impact. Read the full article on Seeking Alpha分析記事 • May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
The analysts might have been a bit too bullish on REGENXBIO Inc. ( NASDAQ:RGNX ), given that the company fell short of...分析記事 • Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
The REGENXBIO Inc. ( NASDAQ:RGNX ) share price has softened a substantial 26% over the previous 30 days, handing back...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 385 | -133 | N/A | -128 | 6 |
| 12/31/2027 | 272 | -188 | N/A | -217 | 8 |
| 12/31/2026 | 236 | -171 | N/A | -149 | 10 |
| 3/31/2026 | 88 | -290 | -236 | -234 | N/A |
| 12/31/2025 | 170 | -194 | -126 | -124 | N/A |
| 9/30/2025 | 161 | -178 | -106 | -103 | N/A |
| 6/30/2025 | 156 | -176 | -91 | -88 | N/A |
| 3/31/2025 | 157 | -158 | -87 | -84 | N/A |
| 12/31/2024 | 83 | -227 | -176 | -173 | N/A |
| 9/30/2024 | 84 | -239 | -185 | -182 | N/A |
| 6/30/2024 | 89 | -241 | -195 | -191 | N/A |
| 3/31/2024 | 87 | -260 | -199 | -193 | N/A |
| 12/31/2023 | 90 | -263 | -228 | -218 | N/A |
| 9/30/2023 | 99 | -261 | -231 | -217 | N/A |
| 6/30/2023 | 97 | -274 | -236 | -218 | N/A |
| 3/31/2023 | 110 | -270 | -257 | -232 | N/A |
| 12/31/2022 | 113 | -280 | -238 | -207 | N/A |
| 9/30/2022 | 480 | 74 | 134 | 173 | N/A |
| 6/30/2022 | 484 | 91 | 128 | 181 | N/A |
| 3/31/2022 | 474 | 101 | 143 | 207 | N/A |
| 12/31/2021 | 470 | 128 | 135 | 219 | N/A |
| 9/30/2021 | 93 | -212 | -166 | -83 | N/A |
| 6/30/2021 | 161 | -145 | -147 | -77 | N/A |
| 3/31/2021 | 156 | -121 | -116 | -63 | N/A |
| 12/31/2020 | 155 | -111 | -81 | -54 | N/A |
| 9/30/2020 | 145 | -91 | -134 | -119 | N/A |
| 6/30/2020 | 61 | -135 | -123 | -112 | N/A |
| 3/31/2020 | 52 | -103 | -128 | -114 | N/A |
| 12/31/2019 | 35 | -95 | N/A | -108 | N/A |
| 9/30/2019 | 64 | -64 | N/A | -86 | N/A |
| 6/30/2019 | 55 | -49 | N/A | -77 | N/A |
| 3/31/2019 | 87 | -37 | N/A | 17 | N/A |
| 12/31/2018 | 219 | 100 | N/A | 105 | N/A |
| 9/30/2018 | 180 | 80 | N/A | 95 | N/A |
| 6/30/2018 | 176 | 78 | N/A | 97 | N/A |
| 3/31/2018 | 142 | 53 | N/A | 18 | N/A |
| 12/31/2017 | 10 | -73 | N/A | -58 | N/A |
| 9/30/2017 | 10 | -77 | N/A | -65 | N/A |
| 6/30/2017 | 9 | -74 | N/A | -59 | N/A |
| 3/31/2017 | 5 | -74 | N/A | -58 | N/A |
| 12/31/2016 | 5 | -63 | N/A | -49 | N/A |
| 9/30/2016 | 7 | -49 | N/A | -33 | N/A |
| 6/30/2016 | 8 | -38 | N/A | -29 | N/A |
| 3/31/2016 | 7 | -32 | N/A | -29 | N/A |
| 12/31/2015 | 8 | -24 | N/A | -23 | N/A |
| 9/30/2015 | 4 | -21 | N/A | -18 | N/A |
| 6/30/2015 | 4 | -16 | N/A | -13 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: RGNX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: RGNX今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: RGNX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: RGNXの収益 ( 33.9% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。
高い収益成長: RGNXの収益 ( 33.9% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: RGNXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 06:24 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
REGENXBIO Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |